Lindsay Rein, MD, Duke University Medical Center, Durham, NC, reviews the evolving treatment landscape of indolent systemic mastocytosis (SM), highlighting long-term follow-up data from the PIONEER study (NCT03731260) of avapritinib, Phase II SUMMIT data for bezuclastinib (NCT05186753), and the HARBOR study of elenestinib (NCT04910685). Dr Rein highlights the role of ultra-sensitive mutation assays in diagnosis and response assessment, and raises the question of whether molecular remission could become a treatment goal in indolent SM. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.